Nature Communications (Nov 2016)
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation
- Pascal Gellert,
- Corrinne V. Segal,
- Qiong Gao,
- Elena López-Knowles,
- Lesley-Ann Martin,
- Andrew Dodson,
- Tiandao Li,
- Christopher A. Miller,
- Charles Lu,
- Elaine R. Mardis,
- Alexa Gillman,
- James Morden,
- Manuela Graf,
- Kally Sidhu,
- Abigail Evans,
- Michael Shere,
- Christopher Holcombe,
- Stuart A. McIntosh,
- Nigel Bundred,
- Anthony Skene,
- William Maxwell,
- John Robertson,
- Judith M. Bliss,
- Ian Smith,
- Mitch Dowsett,
- POETIC Trial Management Group and Trialists
Affiliations
- Pascal Gellert
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Corrinne V. Segal
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Qiong Gao
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Elena López-Knowles
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Lesley-Ann Martin
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Andrew Dodson
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital
- Tiandao Li
- McDonnell Genome Institute, Washington University School of Medicine
- Christopher A. Miller
- McDonnell Genome Institute, Washington University School of Medicine
- Charles Lu
- McDonnell Genome Institute, Washington University School of Medicine
- Elaine R. Mardis
- McDonnell Genome Institute, Washington University School of Medicine
- Alexa Gillman
- Clinical Trials and Statistics Unit at The Institute of Cancer Research
- James Morden
- Clinical Trials and Statistics Unit at The Institute of Cancer Research
- Manuela Graf
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- Kally Sidhu
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital
- Abigail Evans
- Poole General Hospital
- Michael Shere
- Southmead Hospital, Westbury-on-Trym
- Christopher Holcombe
- Royal Liverpool University Hospital
- Stuart A. McIntosh
- Queen’s University Belfast
- Nigel Bundred
- University Hospital of South Manchester, Education and Research Centre
- Anthony Skene
- Royal Bournemouth Hospital, Castle Ln E
- William Maxwell
- Withybush General Hospital
- John Robertson
- University of Nottingham
- Judith M. Bliss
- Clinical Trials and Statistics Unit at The Institute of Cancer Research
- Ian Smith
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital
- Mitch Dowsett
- Breast Cancer Now Research Centre at The Institute of Cancer Research
- POETIC Trial Management Group and Trialists
- DOI
- https://doi.org/10.1038/ncomms13294
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 11
Abstract
Aromatase inhibitors are used to treat oestrogen receptor positive breast cancers but the molecular basis for the response of patients is unclear. Here, the authors use samples from an aromatase inhibitor clinical trial and show that tumours from poor responders have more mutations than good responders and also more frequently harbour p53 mutations.
